Skip to NavigationSkip to content

AbbVie files lawsuit against Amgen over Humira copy

Published on 08/08/16 at 09:00am

Abbvie has filed a patent infringement lawsuit against Amgen over the latter firm’s copy of its Humira (adalimumab) rheumatoid arthritis drug.

The company has asserted that Amgen’s proposed ABP 501 biosimilar would violate at least 10 of its patents and up to as many as 51 other patents, and is seeking a court order to prevent its sale.

In July, the US Food and Drug Administration (FDA) voiced its unanimous recommendation of the biosimilar after calling it ‘highly similar’ to the original Humira.

The active ingredient of ABP 501 is an anti-tumour necrosis factor-alpha (TNF-α) monoclonal antibody which has a similar amino acid sequence as Humira and can be used to treat a ranges of afflictions including rheumatoid and psioriatic arthritis, spondylitis, moderate to severe psoriasis and Crohn’s disease.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches